Literature DB >> 8035049

Human immunodeficiency virus serostatus and the risk of postextraction complications.

T B Dodson1, D H Perrott, R K Gongloff, L B Kaban.   

Abstract

Despite the increasing prevalence of human immunodeficiency virus (HIV) disease in the population and the increasing likelihood that HIV-positive (HIV+) patients may have an extraction, little is known about the risk of postoperative complications in this group. The goal of this investigation was to assess the risk of postoperative complications in HIV+ patients after tooth extraction. The study was designed as a retrospective cohort study with a sample consisting of 145 males who underwent tooth extraction. The patients' medical and dental records were reviewed to identify HIV serostatus, to document the frequency and type of postoperative complications, and to collect data on potential confounding variables. Forty-four patients were identified as HIV+. The postoperative complication rate in HIV+ patients was 20.9% and for HIV-negative (HIV-) patients 2.9% (relative risk = 7.0, 95% confidence interval = 2.0-25.0, P = 0.001). Furthermore, as the manifestations of the symptoms of HIV infection became more severe, the postextraction complication rate also increased (P = 0.008). The results of this study suggest that HIV+ patients have an increased risk of postextraction complications and as the level of HIV disease increases, the risk of complications also increases. While the findings of this study are consistent with studies based on case series, prospective cohort studies are required to confirm the findings.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035049     DOI: 10.1016/s0901-5027(05)80602-2

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  1 in total

1.  Comparison of sensitivity of bacteria isolated in odontogenic infections to ceftriaxone and amoxicillin-clavulanate.

Authors:  Olawale Olatunbosun Adamson; Michael Olayinka Adeyemi; Olalekan Micah Gbotolorun; Omoniyi Omolola Oduyebo; Olalekan Odeniyi; Wasiu Lanre Adeyemo
Journal:  Afr Health Sci       Date:  2019-09       Impact factor: 0.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.